Navigation Links
Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results
Date:5/13/2010

of a Phase 3 registration trial with perifosine in refractory advanced colorectal cancer by Keryx. - April 15, 2010: Positive Scientific Advice from the EMA for the Phase 3 program with perifosine in multiple myeloma. Data from ongoing Phase 3 study, sponsored by Keryx, can be used to register perifosine in multiple myeloma in Europe. - April 20, 2010: Presentations of preclinical data on Erk inhibitor, AEZS-131, and Erk/PI3K dual inhibitor, AEZS-132, as well as preclinical data from a study sponsored by the National Institutes of Health with perifosine in oncology at the American Association for Cancer Research Annual Meeting in Washington, D.C. - April 20, 2010: Completion of a $15.0 million registered direct offering with certain institutional investors. - April, 23, 2010: Company regained compliance with Nasdaq's minimum bid price listing requirement. - May 6, 2010: Company receives orphan-drug designation from the FDA for AEZS-108 in ovarian cancer. - May 12, 2010: FDA approves the Company's Investigational New Drug (IND) application for AEZS-108 in LHRH-receptor positive urothelial (bladder) cancer.

Juergen Engel, Ph.D., Aeterna Zentaris' President and Chief Executive Officer commented, "This has been a very exciting quarter as we made great strides in the development of our lead oncology compound, perifosine, now in Phase 3 registration trials for multiple myeloma and refractory advanced colorectal cancer. Furthermore, the different designations recently granted by the FDA in both indications and the EMA's positive Scientific Advice for multiple myeloma, will accelerate as well as facilitate the future review and marketing authorization processes in North America and Europe."


SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
2. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
3. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
5. AEterna Zentaris Announces Appointment of New Board Member
6. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
7. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
8. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
9. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
10. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
11. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... , May 26, 2015  Alere Inc. (NYSE: ALR ... its failure to timely file its Quarterly Report on Form ... "Form 10-Q"), it has received a notice from the New ... in compliance with the NYSE,s continued listing requirements under the ... Listed Company Manual. The reason for the ...
(Date:5/26/2015)... 2015 OHAUS Corporation, a leading manufacturer ... set to release a new line of Water Analysis ... For over a century, the OHAUS brand has been ... the world. Now in North America, OHAUS is ... to include water quality measurement. The OHAUS Starter Series ...
(Date:5/26/2015)... Pharmaco-Kinesis Corporation (PKC) announced today that its ... on the Beach in Santa Monica, CA ... Company,s innovative Metronomic Biofeedback Pump (MBP), a fully smart ... time to a target site of the human body ... in real-time.  ...
(Date:5/26/2015)... -- Mr. Kevin Xu , President of MEBO International, ... and President Bill Clinton for their sympathy ... Rongxiang Xu , Kevin,s father. As ... time, Dr. Xu,s commitment to the advancement of science and ... not be forgotten. As a renowned life scientist, Dr. Xu ...
Breaking Biology Technology:OHAUS Corporation to Release New Water Analysis Meters in 2015 2OHAUS Corporation to Release New Water Analysis Meters in 2015 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 2Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 4Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 5Dr. Rongxiang Xu, Beyond A Legend 2
... distinguished himself as the first Wisconsin governor elected to four ... the first Wisconsin governor to be tagged with radio frequency ... Tommy Thompson Thompson, who also served as Secretary ... will have one of the security technology firm Applied Digital's ...
... Health System in Milwaukee is expanding its ... clinical information solution and is deploying additional Eclypsis ... Boca Raton, Fla. , ,The additional Eclipsys products ... Secure Health Messaging, and Knowledge-Based Charting, a comprehensive ...
... - The two-year state budget signed into law ... edge of many Wisconsin technology firms by changing how ... the Wisconsin Technology Council. , ,With bipartisan ... extend the "single-sales factor" sales apportionment for corporate income ...
Cached Biology Technology:Tommy Thompson to get RFID implant 2Tommy Thompson to get RFID implant 3`Single-sales factor' extends tax treatment to tech, service firms 2`Single-sales factor' extends tax treatment to tech, service firms 3
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated (NASDAQ: ... interface solutions, today announced the appointment of ... Chief Financial Officer, reporting to Rick Bergman ... current Chief Financial Officer, Kathleen Bayless , ... Mr. Ali brings extensive financial management ...
(Date:5/11/2015)... 2015 Curemark LLC, a privately held drug ... new Phase III double blind, randomized, placebo-controlled clinical trial ... on all children ages 3-8 with Autism. Previously, Curemark ... double blinded clinical trial for CM-AT in children ages ... digestive enzyme chymotrypsin. This new trial will help determine ...
(Date:5/8/2015)... -- Synaptics Inc. (NASDAQ: SYNA ), the leading developer ... executive management team will present at the following investor events: ... Conference Date: May 18, 2015 Time: 10:40am ET ... Cowen and Company Technology, Media & Telecom ... New York Palace Hotel, New York, NY ...
Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2
... University of Alberta researchers determined that a fossilized dinosaur bone ... the age of dinosaurs ended between 65.5 and 66 million ... led by Larry Heaman from the Department of Earth and ... being only 64.8 million years old. That means this particular ...
... The Welch Foundation today awarded its prestigious Hackerman Award ... named this year,s "rising star" for his innovative chemical ... called gold nanostars, which are proving useful for sensing, ... large electrical fields inside cell membranes. "I,ve always ...
... by experts at the University of Exeter has revealed that ... with different dispositions at least in the world of ... such as aggressive behaviour or a willingness to explore, did ... a like-minded partner. Where couples were markedly different in personality, ...
Cached Biology News:Test shows dinosaurs survived mass extinction by 700,000 years 2Rice scientist recognized for stellar work on nanoparticles, cell membranes 2Rice scientist recognized for stellar work on nanoparticles, cell membranes 3Opposites may attract, but they don't make better parents 2
... systems are high-precision microarrayers capable of ... samples. VersArray ChipWriter Pro systems set ... and reproducibility to deliver unparalleled quality ... Their modular component design and flexible ...
Freeze 'N Squeeze DNA gel extraction spin columns use a quick freeze-and-thaw cycle and centrifugation to draw 50-23,000 bp DNA out of agarose gel slices. Supplied as 25 columns....
The SmartSpec printer paper is used to record data generated by the SmartSpec Plus spectrophotometer. Supplied as 5 packs....
The thermal printer, 120 V, is used to record fluorescence data acquired with the VersaFluor fluorometry systems. The printer includes a cable and power adaptor....
Biology Products: